Filing Flows › Comparisons › SPRO vs OTLC
Spero Therapeutics vs Oncotelic Therapeutics: SPRO and OTLC compared
Spero Therapeutics is the larger company: $258K of revenue in its latest quarter (Q1 2026) against $250K for Oncotelic Therapeutics (Q2 2026).
Where the money goes: SPRO and OTLC
Spero Therapeutics (SPRO) · Q1 2026
Spero Therapeutics, Q1 2026: revenue $258K (-96% year over year), net loss $7.2M, operating cash flow $15.9M. The chart follows the revenue to costs, profit and cash.
Oncotelic Therapeutics (OTLC) · Q2 2026
Oncotelic Therapeutics, Q2 2026: revenue $250K, operating margin -337.4%, net earnings $341K, operating cash flow −$92K. The chart follows the revenue to costs, profit and cash.
| Spero Therapeutics (SPRO) | Oncotelic Therapeutics (OTLC) | |
|---|---|---|
| Latest quarter | Q1 2026 | Q2 2026 |
| Revenue | $258K | $250K |
| Revenue growth, Y/Y | -96% | — |
| Operating margin | n/m | -337.4% |
| Net earnings | −$7.2M | $341K |
| Net margin | — | 136.4% |
| Operating cash flow | $15.9M | −$92K |
Questions
Which is bigger, Spero Therapeutics or Oncotelic Therapeutics?
Spero Therapeutics is the larger company: $258K of revenue in its latest quarter (Q1 2026) against $250K for Oncotelic Therapeutics (Q2 2026).
More: Spero Therapeutics earnings · how Spero Therapeutics makes money · Oncotelic Therapeutics earnings · how Oncotelic Therapeutics makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed May 13, 2026; 10-Q filed Aug 13, 2026). Fiscal quarters can end on different dates. Not investment advice.